retatrutide clinical trial results 2024 Lilly's 'triple G' agonist triumphs in Phase III trial, but AEs unnerve analysts Retatrutide Availability & Timeline |

Elevated fasting insulin, visceral adiposity, non-alcoholic fatty liver disease, and chronic systemic inflammation are not merely cardiovascular or endocrine risk factors they represent a hostile cellular environment in which neoplastic transformation is more likely to occur, progress, and evade immune surveillance

What matters is steady protein intake over time, not perfection at every meal

GLP-1 medications have been shown to restore ovulation in women who weren't ovulating regularly

The FDA warning applies only to medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), which are different from common thyroid cancers